Assertio presents new data from study of SYMPAZAN Oral Film

Assertio (ASRT) announced new data from a first-ever real-world study of SYMPAZAN Oral Film. The data were presented at the 150th Annual Meeting of the American Neurological Association as a poster titled “M266: Real-World Evidence Study of Patients with Lennox-Gastaut Syndrome Taking Clobazam Oral Soluble Film: Demographics, Medications, and Comorbidities.” Based on analyses of data collected over a ten-year period, study authors reached the following conclusions. In this real-world study of patients with epilepsy or LGS receiving clobazam oral soluble film, patients displayed varying demographics, additional medication use, and comorbidities. Patients in the LGS subset tended to be younger in age, more often switched from clobazam tablets or suspension, and had higher cannabidiol use than those in the epilepsy group. These data provide valuable insights describing patients with epilepsy or LGS and their use of clobazam oral film.